GCP
STLN

GSA Capital Partners’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

GSA Capital Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$536K Buy
+98,727
New +$415K 0.03% 957
2026
Q1 		– Sell
-70,654
Closed -$252K – 2157
2025
Q4 		$252K Buy
+70,654
New +$262K 0.02% 1270
2025
Q2 		– Sell
-28,529
Closed -$33K – 2152
2025
Q1 		$33K Buy
+28,529
New +$22.1K ﹤0.01% 1567

Other funds holding STLN

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IAAG
Innovative Asset Advisors Group Shelton, Connecticut $229M AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

GSA Capital Partners's STLN Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q2 2026: 98,727 shares worth $536K. The stake represents 0.03% of the portfolio and ranks #957 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in STLN as recently as Q4 2025.

GSA Capital Partners first reported a position in STLN in Q1 2025 and has held it in 3 quarters since. 26 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • GSA Capital Partners held 98,727 shares of Starling Oncology Institute, Inc. Common Stock worth $536K as of Q2 2026.
  • Starling Oncology Institute, Inc. Common Stock was a new GSA Capital Partners position in Q2 2026.
  • Starling Oncology Institute, Inc. Common Stock made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #957 holding.
  • GSA Capital Partners first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2025 and has held it in 3 quarters since.
  • 26 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.